Arcus Biosciences, Inc.
Clinical trials sponsored by Arcus Biosciences, Inc., explained in plain language.
-
New combo therapy aims to slow advanced kidney cancer
Disease control Recruiting nowThis study tests whether adding the experimental drug casdatifan to the standard drug cabozantinib helps people with advanced clear cell kidney cancer live longer without their cancer growing. About 720 adults whose cancer worsened after prior immunotherapy will receive either ca…
Phase: PHASE3 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New hope for kidney cancer: experimental drug AB521 enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug called AB521 (casdatifan) in people with advanced kidney cancer or other solid tumors that have not responded to standard treatments. The study will first find a safe dose of AB521 alone, then test it alone or combined with other cancer dru…
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC